1
|
Kim W, Watt CL, Enright P, Sikora L, Zwicker J. Management of Motor Symptoms for Patients with Advanced Parkinson's Disease without Safe Oral Access: A Scoping Review. J Palliat Med 2023; 26:131-141. [PMID: 36126303 DOI: 10.1089/jpm.2022.0193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Context: Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide. Oral medications for control of motor symptoms are the mainstay of treatment. However, as the disease progresses, patients with PD may develop dysphagia that prohibits them from safely taking oral medications. Currently there are no clinical guidelines for managing distressing motor symptoms in patients with PD and severe dysphagia, which can therefore be quite challenging. Objectives: To provide an exhaustive summary of current literature on pharmacological interventions for patients with PD who do not have safe oral access in managing distressing motor symptoms. Indication, route, doses, frequency, outcome, and adverse effects will be discussed. Methods: A scoping review using Medline, Embase, CENTRAL, CINAHL, AgeLine, and PsycINFO databases (1946-2021) was conducted. Articles examining patients with PD and dysphagia who are eligible to receive palliative care or at end of life were included. Studies that included patients who were also on oral PD medications or received device-aided therapy were excluded from this review. Results: A total of 3821 articles were screened for title and abstract, 259 were selected for full-text review, and 20 articles were selected for data extraction. These included five case reports, one retrospective cohort study, one book chapter, and 13 narrative reviews. There are very few articles addressing the issue of treatment of patients with advanced PD who are unable to take oral medications. Although rotigotine patch and apormorphine injections are most frequently recommended, there are no clinical trials in this patient population to support those recommendations. Conclusion: This study highlights a need for further research examining the efficacy and dosing of nonoral medications in advanced PD with dysphagia.
Collapse
Affiliation(s)
- WooJin Kim
- Division of Neurology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.,Division of Palliative Care, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
| | - Christine L Watt
- Division of Palliative Care, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.,Bruyère Research Institute, Ottawa, Ontario, Canada.,Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Paula Enright
- Division of Palliative Care, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.,Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Lindsey Sikora
- Health Sciences Library, University of Ottawa, Ottawa, Ontario, Canada
| | - Jocelyn Zwicker
- Division of Neurology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.,Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| |
Collapse
|
2
|
Huang Y, Wang P, Morales R, Luo Q, Ma J. Map2k5-Deficient Mice Manifest Phenotypes and Pathological Changes of Dopamine Deficiency in the Central Nervous System. Front Aging Neurosci 2021; 13:651638. [PMID: 34168549 PMCID: PMC8217467 DOI: 10.3389/fnagi.2021.651638] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2021] [Accepted: 05/03/2021] [Indexed: 02/05/2023] Open
Abstract
MAP2K5, a member of the MAPK family, is associated with central nervous system disorders. However, neural functional of Map2k5 from animal models were not well examined so far. Here, we established a Map2k5-targeted knockout mouse model to investigate the behavior phenotypes and its underlying molecular mechanism. Our results showed that female Map2k5 mutant mice manifested decreased circadian-dependent ambulatory locomotion, coordination, and fatigue. Male Map2k5 mutant mice displayed impairment in open field exploration and prepulse inhibition of acoustic startle response (ASR) when compared with wild-type controls. Furthermore, Map2k5 mutant mice showed a decreased dopaminergic cell survival and tyrosine hydroxylase levels in nigrostriatal pathway, indicating a crucial role of MAP2K5 in regulating dopamine system in the central nervous system. In conclusion, this is the first study demonstrating that Map2k5 mutant mice displayed phenotypes by disturbing the dopamine system in the central nervous system, implicating Map2k5 mutant mouse as a promising model for many dopamine related disorders.
Collapse
Affiliation(s)
- Yumeng Huang
- Department of Neurology, Institute of Neurology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China
| | - Pei Wang
- Department of Neurology, Institute of Neurology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China
| | - Rodrigo Morales
- Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.,Centro Integrativo de Biologia y Quimica Aplicada (CIBQA), Universidad Bernardo O'Higgins, Santiago, Chile
| | - Qi Luo
- Department of Neurology, Institute of Neurology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China
| | - Jianfang Ma
- Department of Neurology, Institute of Neurology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China
| |
Collapse
|
3
|
Luo H, Zhao Y, Jin X, Yang J, Cong H, Ge Q, Sun L, Liu M, Tao Z. Voltammetric Detection of Catechol and Dopamine Based on a Supramolecular Composite Prepared from Multifarene[3,3] and Reduced Graphene Oxide. ELECTROANAL 2020. [DOI: 10.1002/elan.201900772] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Huan Luo
- Key Laboratory of Macrocyclic and Supramolecular Chemistry of Guizhou ProvinceGuizhou University Guiyang 550025 China
| | - Yong‐Yi Zhao
- Key Laboratory of Macrocyclic and Supramolecular Chemistry of Guizhou ProvinceGuizhou University Guiyang 550025 China
| | - Xian‐Yi Jin
- School of Materials and Metallurgical EngineeringGuizhou Institute of Technology Guiyang 550001 China
| | - Jian‐Mei Yang
- Key Laboratory of Macrocyclic and Supramolecular Chemistry of Guizhou ProvinceGuizhou University Guiyang 550025 China
| | - Hang Cong
- Key Laboratory of Macrocyclic and Supramolecular Chemistry of Guizhou ProvinceGuizhou University Guiyang 550025 China
| | - Qing‐Mei Ge
- Key Laboratory of Macrocyclic and Supramolecular Chemistry of Guizhou ProvinceGuizhou University Guiyang 550025 China
| | - Lin Sun
- Guizhou Shengyang Pipeline Technology Co., Ltd Guiding 551302 China
| | - Mao Liu
- Key Laboratory of Macrocyclic and Supramolecular Chemistry of Guizhou ProvinceGuizhou University Guiyang 550025 China
| | - Zhu Tao
- Key Laboratory of Macrocyclic and Supramolecular Chemistry of Guizhou ProvinceGuizhou University Guiyang 550025 China
| |
Collapse
|
4
|
Panta P, Sarode SC, Sarode GS, Gadbail AR, Gondivkar SM, Patiln S. "Mind" in Betel-quid Use and Related Disorders. J Contemp Dent Pract 2018; 19:629-630. [PMID: 29959286 DOI: 10.5005/jp-journals-10024-2309] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/13/2023]
Abstract
Oral squamous cell carcinoma is characterized by a unique predisposing state called oral potentially malignant disorders (OPMDs). Wide variety of carcinogenic insult in the form of detrimental habits can contribute to the causation of variety of OPMDs.1,2.
Collapse
Affiliation(s)
- Prashanth Panta
- Department of Oral Medicine and Radiology, MNR Dental College & Hospital, Sangareddy, Telangana, India, Phone: +919701806830, e-mail:
| | - Sachin C Sarode
- Department of Oral Pathology and Microbiology, Dr. D. Y. Patil Dental College & Hospital, Dr. D. Y. Patil Vidyapeeth, Pune Maharashtra, India
| | - Gargi S Sarode
- Department of Oral Pathology and Microbiology, Dr. D. Y. Patil Dental College & Hospital, Dr. D. Y. Patil Vidyapeeth, Pune Maharashtra, India
| | - Amol R Gadbail
- Department of Dentistry, Indira Gandhi Government Medical College & Hospital, Nagpur, Maharashtra, India
| | - Shailesh M Gondivkar
- Department of Oral Medicine and Radiology, Government Dental College & Hospital, Nagpur, Maharashtra, India
| | - Shankargouda Patiln
- Division of Oral Pathology, Department of Maxillofacial Surgery and Diagnostic Sciences, College of Dentistry, Jazan University Jazan, Kingdom of Saudi Arabia
| |
Collapse
|
5
|
Sabel BA, Cárdenas-Morales L, Gao Y. Vision Restoration in Glaucoma by Activating Residual Vision with a Holistic, Clinical Approach: A Review. J Curr Glaucoma Pract 2018; 12:1-9. [PMID: 29861576 PMCID: PMC5981087 DOI: 10.5005/jp-journals-10028-1237] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2017] [Accepted: 11/22/2017] [Indexed: 01/07/2023] Open
Abstract
How to cite this article: Sabel BA, Cárdenas-Morales L, Gao Y. Vision Restoration in Glaucoma by activating Residual Vision with a Holistic, Clinical Approach: A Review. J Curr Glaucoma Pract 2018;12(1):1-9.
Collapse
Affiliation(s)
- Bernhard A Sabel
- Professor, SAVIR Center, Magdeburg, Germany; Institute for Medical Psychology, Otto von Guericke University of Magdeburg Magdeburg, Germany
| | - Lizbeth Cárdenas-Morales
- Lecturer, Institute for Medical Psychology, Otto von Guericke University of Magdeburg, Magdeburg, Germany
| | - Ying Gao
- Researcher, SAVIR Center, Magdeburg, Germany; Institute for Medical Psychology, Otto von Guericke University of Magdeburg Magdeburg, Germany
| |
Collapse
|
6
|
Ceravolo R, Rossi C, Del Prete E, Bonuccelli U. A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease. Expert Opin Drug Saf 2016; 15:181-98. [PMID: 26646536 DOI: 10.1517/14740338.2016.1130128] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
INTRODUCTION Dopamine agonists are highly effective as adjunctive therapy to levodopa in advanced Parkinson's disease. These drugs have rapidly gained popularity as a monotherapy in the early stages of Parkinson's disease for patients less than 65-70 years old since they are about as effective as levodopa but patients demonstrate a lower tendency to develop motor complications. However, dopamine agonists could have peripheral and central side-effects which are often the reason for the discontinuation of the treatment. AREAS COVERED This article presents an overview of the efficacy and the potential negative effects related to the use of dopamine agonists in the treatment of Parkinson's disease. EXPERT OPINION Beyond the new generation non ergot dopamine agonists, no strong evidences allow the choice of a specific dopamine agonists for Parkinson 's disease treatment and by now dopamine agonists treatment should be tailored on specific adverse events profile.
Collapse
Affiliation(s)
- Roberto Ceravolo
- a Department of Clinical and Experimental Medicine , University of Pisa , Pisa , Italy.,b Department of Neurosciences, Neurology Unit , AOU-Pisa , Pisa , Italy
| | - Carlo Rossi
- a Department of Clinical and Experimental Medicine , University of Pisa , Pisa , Italy.,b Department of Neurosciences, Neurology Unit , AOU-Pisa , Pisa , Italy
| | - Eleonora Del Prete
- a Department of Clinical and Experimental Medicine , University of Pisa , Pisa , Italy.,b Department of Neurosciences, Neurology Unit , AOU-Pisa , Pisa , Italy
| | - Ubaldo Bonuccelli
- a Department of Clinical and Experimental Medicine , University of Pisa , Pisa , Italy.,b Department of Neurosciences, Neurology Unit , AOU-Pisa , Pisa , Italy
| |
Collapse
|
7
|
Farlow MR, Somogyi M. Transdermal patches for the treatment of neurologic conditions in elderly patients: a review. Prim Care Companion CNS Disord 2012; 13:11r01149. [PMID: 22454804 DOI: 10.4088/pcc.11r01149] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2011] [Accepted: 05/18/2011] [Indexed: 10/14/2022] Open
Abstract
OBJECTIVE The mode of drug delivery can be an important consideration in optimizing drug therapy, as it can affect treatment compliance and outcomes. It is particularly important to develop optimal drug formulations for chronic diseases or conditions in the elderly for which treatment compliance is known to be low. In this review, the features and benefits of transdermal formulations for treating neurologic conditions in elderly patients are described. DATA SOURCES English-language articles were identified by searching MEDLINE in November 2010 (there were no search parameters on date of publication) using the search terms transdermal patch, transdermal system, neurology, rivastigmine, rotigotine, selegiline, lidocaine, capsaicin, compliance, and neuropathic pain. DATA SELECTION Articles describing the development, use, efficacy, and safety of licensed transdermal patch treatments for neurologic conditions that affect the elderly were included. DATA EXTRACTION The features of transdermal systems and comparisons between transdermal and oral formulations for the treatment of specific neurologic conditions in elderly patients were reviewed. DATA SYNTHESIS There are 5 transdermal patch systems currently available for neurologic conditions in adults: rivastigmine, rotigotine, selegiline, lidocaine, and capsaicin. These are all modern formulations in matrix patches, developed to provide appropriate drug dosage in an acceptable and well-tolerated form. CONCLUSIONS Transdermal patches can offer benefits to patients over oral formulations in terms of ease of use, simple treatment regimens, avoidance of the first-pass effect, and avoidance of high maximum plasma concentrations with rapid changes in drug levels, without the invasive procedures associated with intravenous treatment.
Collapse
Affiliation(s)
- Martin R Farlow
- Department of Neurology, Indiana University School of Medicine, Indianapolis (Dr Farlow); and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey (Dr Somogyi)
| | | |
Collapse
|
8
|
Gilmour TP, Piallat B, Lieu CA, Venkiteswaran K, Ramachandra R, Rao AN, Petticoffer AC, Berk MA, Subramanian T. The effect of striatal dopaminergic grafts on the neuronal activity in the substantia nigra pars reticulata and subthalamic nucleus in hemiparkinsonian rats. ACTA ACUST UNITED AC 2011; 134:3276-89. [PMID: 21911417 DOI: 10.1093/brain/awr226] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
The electrophysiological correlates of parkinsonism in the basal ganglia have been well studied in patients with Parkinson's disease and animal models. Separately, striatal dopaminergic cell transplantation has shown promise in ameliorating parkinsonian motor symptoms. However, the effect of dopaminergic grafts on basal ganglia electrophysiology has not thoroughly been investigated. In this study, we transplanted murine foetal ventral mesencephalic cells into rats rendered hemiparkinsonian by 6-hydroxydopamine injection. Three months after transplantation, extracellular and local field potential recordings were taken under urethane anaesthesia from the substantia nigra pars reticulata and subthalamic nucleus along with cortical electroencephalograms and were compared to recordings from normal and hemiparkinsonian controls. Recordings from cortical slow-wave activity and global activation states were analysed separately. Rats with histologically confirmed xenografts showed behavioural improvement measured by counting apomorphine-induced rotations and with the extended body axis test. Firing rates in both nuclei were not significantly different between control and grafted groups. However, burst firing patterns in both nuclei in the slow-wave activity state were significantly reduced (P < 0.05) in rats with large surviving grafts, compared to hemiparkinsonian controls. The neuronal firing entropies and oscillations in both nuclei were restored to normal levels in the large-graft group. Electroencephalogram spike-triggered averages also showed normalization in the slow-wave activity state (P < 0.05). These results suggest that local continuous dopaminergic stimulation exerts a normalizing effect on the downstream parkinsonian basal ganglia firing patterns. This novel finding is relevant to future preclinical and clinical investigations of cell transplantation and the development of next-generation therapies for Parkinson's disease that ameliorate pathophysiological neural activity and provide optimal recovery of function.
Collapse
Affiliation(s)
- Timothy P Gilmour
- Department of Neurology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Wu A, Wagner ML. Rotigotine transdermal system for the treatment of restless legs syndrome. FUTURE NEUROLOGY 2009. [DOI: 10.2217/fnl.09.9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Rotigotine is a nonergot D3, D2 and D1 dopamine agonist that is currently approved for use in Parkinson’s disease and is awaiting approval for restless legs syndrome (RLS) in Europe. In the USA, it is currently approved for the treatment of early-stage Parkinson’s disease, but not for RLS patients. Oral dopaminergic agents are considered first-line for the treatment of RLS, but may not benefit all patients. Transdermally administered rotigotine delivers medication continuously, which may benefit patients with more severe RLS symptoms that persist or fluctuate throughout the day. It may also benefit patients with gastrointestinal problems or difficulty swallowing. Future research may further define the benefits of minimizing pulsatile stimulation of dopamine receptors. Several studies support the efficacy and tolerability of rotigotine in RLS patients. After treatment with rotigotine, patients had improved International RLS scores compared with placebo. Side effects reported were generally not serious and included application site reaction, nausea, somnolence, dizziness, headache, vomiting and insomnia. The well-known effectiveness and tolerability of dopaminergics, combined with a new pharmaceutical form, represents a promising treatment option for patients with RLS.
Collapse
Affiliation(s)
- Anny Wu
- Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA
| | - Mary L Wagner
- Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA
| |
Collapse
|
10
|
Bonuccelli U, Ceravolo R. The safety of dopamine agonists in the treatment of Parkinson's disease. Expert Opin Drug Saf 2008; 7:111-27. [PMID: 18324875 DOI: 10.1517/14740338.7.2.111] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Dopamine agonists are highly effective as adjunctive therapy to levodopa in advanced Parkinson's disease. These drugs have rapidly gained popularity as a monotherapy in the early stages of Parkinson's disease for patients < 65-70 years old, because they are about as effective as levodopa, but patients demonstrate a lower tendency to develop motor complications. However, dopamine agonists could have peripheral and central side effects, which are often the reason for the discontinuation of the treatment. This review focuses on the potential negative effects related to the use of dopamine agonists in the treatment of Parkinson's disease.
Collapse
Affiliation(s)
- Ubaldo Bonuccelli
- University of Pisa, Department of Neuroscience, Via Roma, 67 56100 Pisa, Italy.
| | | |
Collapse
|
11
|
Abstract
Safe, effective drug therapy in older adults requires an understanding of drug disposition and response in this population. Evidence suggests that physiologic changes during aging, including hepatic or renal function changes, contribute to pharmacokinetic differences. A major issue surrounding the study of older adults relates to the ability to study a large number of people in a minimally invasive way. Population pharmacokinetics provides a potential means of addressing this issue and a tool to evaluate drug exposure's magnitude and consistency. This article highlights examples of pharmacokinetic studies in psychiatry, in particular those conducted in older adults. It also reviews new drugs approved for treatment in psychiatry or neurology, many of which were developed as novel formulations (eg, extended-release transdermal film) with improved pharmacokinetic profiles or developed with regard to the actions of a specific enantiomer or metabolite.
Collapse
Affiliation(s)
- Kristin L Bigos
- Department of Pharmaceutical Sciences, University of Pittsburgh, 3501 Terrace Street, 805 Salk Hall, Pittsburgh, PA 15261, USA
| | | | | |
Collapse
|
12
|
Kenney C, Jankovic J. Rotigotine transdermal patch in the treatment of Parkinson’s disease and restless legs syndrome. Expert Opin Pharmacother 2007; 8:1329-35. [PMID: 17563266 DOI: 10.1517/14656566.8.9.1329] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Dopamine agonists are effective in delaying levodopa-induced dyskinesia in early Parkinson's disease (PD) and reducing motor fluctuations in advanced PD. Rotigotine, a novel dopamine receptor agonist, improves motor function in both early and advanced PD using a transdermal route of administration. A smaller, but convincing body of data, supports its ability to ameliorate the symptoms of restless legs syndrome as well. The side-effect profile mimics other dopamine agonists, with the addition of application-site reactions, most of which are mild-to-moderate. Advantages over existing dopamine agonists include once-daily administration, absence of food interactions, maintenance of stable plasma levels and utility in patients with swallowing difficulties.
Collapse
Affiliation(s)
- Christopher Kenney
- Parkinson's disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, Texas 77030, USA.
| | | |
Collapse
|